Reality Check

MMIT Reality Check on Major Depressive Disorder (Mar 2019)

March 8, 2019

According to our recent payer coverage analysis for major depressive disorder treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for major depressive disorder treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for major depressive disorder treatments shows that under the pharamcy benefit, more than 47% of the covered lives in commercial formularies have utilization management restrictions.

Trends: In November 2018, CMS issued a proposed rule that would let Medicare Advantage and Part D plans limit coverage of certain drugs in the six “protected classes,” which include antidepressants and antipsychotics. Wall Street analysts viewed the proposal as good news for managed care firms . Via AIS Health.

MMIT Reality Check on Hereditary Angioedema (Mar 2018)

March 1, 2019

According to our recent payer coverage analysis for Hereditary Angioedema (HAE) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for Hereditary Angioedema (HAE) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: Under the pharmacy benefit, more than 63% of the covered lives under commercial formularies have utilization management restrictions.

Trends: Management of HAE cannot simply be a one-size-fits-all approach, as the condition is variable and patient specific. Via AIS Health.

MMIT Reality Check on HIV (Feb 2019)

February 22, 2019

According to our recent payer coverage analysis for HIV treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for HIV treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for HIV treatments shows that under the pharamcy benefit, more than 75% of the covered lives in commercial formularies have utilization management restrictions.

Trends: Contracting is prevalent for drugs in the same HIV grouping, with most activity focused on tiering preference. Patent expirations are expected for single agents. Via AIS Health.

MMIT Reality Check on Rheumatoid Arthritis (Feb 2019)

February 15, 2019

According to our recent payer coverage analysis for rheumatoid arthritis (RA) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for rheumatoid arthritis (RA) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for RA treatments shows that about 73% of the covered lives under the commercial formularies are covered with utilization management restrictions.

Trends: With more biosimilars coming to market to compete against some of the older biologic-based drugs, an industry expert suggests that the RA market will see more competition. Via AIS Health.

MMIT Reality Check on Type 2 Diabetes (Feb 2019)

February 8, 2019

According to our recent payer coverage analysis for type 2 diabetes treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for type 2 diabetes treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for type 2 diabetes treatments shows that almost half of the lives under the commercial and health exchange formularies have utilization management restrictions.

Trends: Health insurers are targeting diabetes via prevention programs and technology. Via AIS Health.

MMIT Reality Check on Neutropenia (Feb 2019)

February 1, 2019

According to our recent payer coverage analysis for neutropenia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for neutropenia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for neutropenia treatments shows that about 40% of the covered lives under the pharmacy benefit in commercial and health exchange formularies have utilization management restrictions.

Trends: The surge of pipeline biosimilars will mean increased competition. Granix and Zarxio utilization is on the rise, which is taking market share from Neulasta and Neupogen . Via AIS Health.